DE3590766C2 - - Google Patents

Info

Publication number
DE3590766C2
DE3590766C2 DE3590766A DE3590766A DE3590766C2 DE 3590766 C2 DE3590766 C2 DE 3590766C2 DE 3590766 A DE3590766 A DE 3590766A DE 3590766 A DE3590766 A DE 3590766A DE 3590766 C2 DE3590766 C2 DE 3590766C2
Authority
DE
Germany
Prior art keywords
proteins
peptides
genes
clones
stochastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3590766A
Other languages
German (de)
English (en)
Other versions
DE3590766T (enExample
Inventor
Marc Genf/Geneve Ch Ballivet
Stuart Alan Bryn Mawr Pa. Us Kauffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kauffmann Stuart Alan Santa Fe Nmex Us
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3590766(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3590766C2 publication Critical patent/DE3590766C2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE3590766A 1985-03-30 1985-06-17 Expired - Lifetime DE3590766C2 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH137985 1985-03-30

Publications (1)

Publication Number Publication Date
DE3590766C2 true DE3590766C2 (enExample) 1991-01-10

Family

ID=4209046

Family Applications (7)

Application Number Title Priority Date Filing Date
DE19853590766 Pending DE3590766T (enExample) 1985-03-30 1985-06-17
DE3590766A Expired - Lifetime DE3590766C2 (enExample) 1985-03-30 1985-06-17
DE3546806A Expired - Lifetime DE3546806C2 (enExample) 1985-03-30 1985-06-17
DE198585902946T Pending DE229046T1 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3587814T Expired - Lifetime DE3587814T2 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3546807A Expired - Lifetime DE3546807C2 (enExample) 1985-03-30 1985-06-17
DE3588239T Expired - Lifetime DE3588239T3 (de) 1985-03-30 1985-06-17 Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19853590766 Pending DE3590766T (enExample) 1985-03-30 1985-06-17

Family Applications After (5)

Application Number Title Priority Date Filing Date
DE3546806A Expired - Lifetime DE3546806C2 (enExample) 1985-03-30 1985-06-17
DE198585902946T Pending DE229046T1 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3587814T Expired - Lifetime DE3587814T2 (de) 1985-03-30 1985-06-17 Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
DE3546807A Expired - Lifetime DE3546807C2 (enExample) 1985-03-30 1985-06-17
DE3588239T Expired - Lifetime DE3588239T3 (de) 1985-03-30 1985-06-17 Verfahren zum Erhalten von DNS, RNS, Peptiden, Polypeptiden oder Proteinen durch DMS-Rekombinant-Verfahren

Country Status (14)

Country Link
US (7) US5723323A (enExample)
EP (3) EP0590689B2 (enExample)
JP (4) JP2584613B2 (enExample)
CN (1) CN86102090A (enExample)
AU (1) AU4434585A (enExample)
CA (2) CA1339937C (enExample)
CH (1) CH0229046H1 (enExample)
DE (7) DE3590766T (enExample)
FR (1) FR2579618B1 (enExample)
GB (1) GB2183661B (enExample)
HK (1) HK20292A (enExample)
IN (2) IN165561B (enExample)
SG (1) SG7992G (enExample)
WO (1) WO1986005803A1 (enExample)

Families Citing this family (778)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866363A (en) * 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
US20060008806A1 (en) * 1986-07-17 2006-01-12 University Of Washington Method for producing novel DNA sequence with biological activity
US5824469A (en) * 1986-07-17 1998-10-20 University Of Washington Method for producing novel DNA sequences with biological activity
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US7413537B2 (en) 1989-09-01 2008-08-19 Dyax Corp. Directed evolution of disulfide-bonded micro-proteins
JP3127158B2 (ja) * 1989-10-05 2001-01-22 オプテイン，インコーポレイティド 新規の遺伝子及びポリペチドの無細胞合成並びに単離
CA2075974C (en) * 1990-02-15 2001-02-06 Dana M. Fowlkes Totally synthetic affinity reagents
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5849890A (en) * 1990-06-11 1998-12-15 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6232071B1 (en) * 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6465189B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5837834A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5750342A (en) * 1990-06-11 1998-05-12 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5637459A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5726017A (en) * 1990-06-11 1998-03-10 Nexstar Pharmaceuticals, Inc. High affinity HIV-1 gag nucleic acid ligands
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5731424A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
EP0786469B1 (en) * 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US6762290B1 (en) * 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
AU2313392A (en) * 1991-08-01 1993-03-02 University Research Corporation Systematic polypeptide evolution by reverse translation
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5656467A (en) * 1992-01-09 1997-08-12 The Trustees Of The University Of Pennsylvania Methods and materials for producing gene libraries
DE69333669T2 (de) * 1992-03-16 2006-03-09 Wohlstadter, Jacob N. Mutagenese und selektionsmethoden in den selben wirtszellen
US5869644A (en) * 1992-04-15 1999-02-09 The Johns Hopkins University Synthesis of diverse and useful collections of oligonucleotidies
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
JPH09504522A (ja) * 1993-10-12 1997-05-06 グリコメド・インコーポレイテッド 細胞接着インヒビターの同定に有用なグリコ−ペプチドのライブラリー
EP0744958B1 (en) 1994-01-31 2003-06-25 Trustees Of Boston University Polyclonal antibody libraries
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6117679A (en) * 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) * 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US6010861A (en) * 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
CA2200684A1 (en) * 1994-09-21 1996-03-28 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
ATE274520T1 (de) * 1995-05-03 2004-09-15 Gilead Sciences Inc Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
US6013443A (en) * 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
ATE343638T1 (de) 1995-06-02 2006-11-15 Gilead Sciences Inc Oligonukleotidliganden mit hoher affinität für pdgf
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
JP4335975B2 (ja) * 1995-06-07 2009-09-30 ギリード・サイエンシズ・インコーポレーテッド Ｄｎａポリメラーゼに対する結合・阻害核酸リガンド
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5797870A (en) * 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
US6475806B1 (en) 1995-06-07 2002-11-05 Praecis Pharmaceuticals, Inc. Anchor libraries and identification of peptide binding sequences
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US20090118481A1 (en) * 1995-06-07 2009-05-07 Gilead Sciences, Inc. High Affinity Nucleic Acid Ligands To Lectins
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6939689B2 (en) 1995-12-07 2005-09-06 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US5830696A (en) 1996-12-05 1998-11-03 Diversa Corporation Directed evolution of thermophilic enzymes
US20020164580A1 (en) * 1995-12-07 2002-11-07 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US7018793B1 (en) * 1995-12-07 2006-03-28 Diversa Corporation Combinatorial screening of mixed populations of organisms
US6537776B1 (en) * 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US20020028443A1 (en) * 1999-09-27 2002-03-07 Jay M. Short Method of dna shuffling with polynucleotides produced by blocking or interrupting a synthesis or amplification process
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6740506B2 (en) 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
DE69722176T2 (de) 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6838238B1 (en) 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6355426B2 (en) 1996-10-31 2002-03-12 Smithkline Beecham Corporation Methods for the characterization and selection of RNA target motifs that bind compounds of pharmaceutical use
US20070009930A1 (en) * 1996-12-18 2007-01-11 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
EP2261373A3 (en) 1997-01-17 2011-12-14 Codexis Mayflower Holdings, LLC Evolution of whole cells and organisms by recursive sequence recombination
US8207093B2 (en) * 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
JP3692542B2 (ja) 1997-01-21 2005-09-07 ザ ジェネラル ホスピタル コーポレーション Ｒｎａ−蛋白質の融合体を用いた蛋白質の選抜
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
US6153410A (en) * 1997-03-25 2000-11-28 California Institute Of Technology Recombination of polynucleotide sequences using random or defined primers
US6180341B1 (en) 1997-05-01 2001-01-30 Board Of Regents, The Universiry Of Texas System In vitro scanning saturation mutagenesis of proteins
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
AU1449499A (en) 1997-10-31 1999-05-24 Maxygen, Incorporated Modification of virus tropism and host range by viral genome shuffling
AU746786B2 (en) * 1997-12-08 2002-05-02 California Institute Of Technology Method for creating polynucleotide and polypeptide sequences
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20030219803A1 (en) * 1997-12-15 2003-11-27 Somalogic, Incorporated Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
US7390619B1 (en) 1998-02-11 2008-06-24 Maxygen, Inc. Optimization of immunomodulatory properties of genetic vaccines
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
FR2782325B1 (fr) * 1998-08-12 2002-05-24 Proteus Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
US7157083B2 (en) * 1998-04-17 2007-01-02 Surrogate Pharmaceutical Pathways, Llc Compositions and methods for treating retroviral infections
EP1073670A1 (en) 1998-05-01 2001-02-07 Maxygen, Inc. Optimization of pest resistance genes using dna shuffling
US7153655B2 (en) 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
DE69941193D1 (de) 1998-08-17 2009-09-10 Bristol Myers Squibb Co Identifizierung von verbindung-protein wechselwirkungen mit bibliotheken von gekoppelten protein-nukleinsäure-molekülen
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
US20020128462A1 (en) * 2000-10-30 2002-09-12 Yi Hu Novel human 7TM proteins and polynucleotides encoding the same
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
AU774306B2 (en) * 1999-01-05 2004-06-24 Trustees Of Boston University Improved nucleic acid cloning
AU2415200A (en) * 1999-01-18 2000-08-01 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20070065838A1 (en) * 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20090130718A1 (en) * 1999-02-04 2009-05-21 Diversa Corporation Gene site saturation mutagenesis
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
CA2362737A1 (en) 1999-03-05 2000-09-08 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7332308B1 (en) 1999-05-21 2008-02-19 The Penn State Research Foundation Incrementally truncated nucleic acids and methods of making same
US6280943B1 (en) * 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
JP4737903B2 (ja) 1999-07-07 2011-08-03 ザイモジェネティクス， インコーポレイテッド ヒトサイトカイン受容体
US6387620B1 (en) * 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
ATE428719T1 (de) * 1999-07-29 2009-05-15 Gilead Sciences Inc Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US20020049312A1 (en) * 2000-05-23 2002-04-25 Turner C. Alexander Noel human thrombospondin-like proteins and polynucleotides encoding the same
US6797510B1 (en) 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6841377B1 (en) 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6586230B1 (en) 2000-10-27 2003-07-01 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6593125B2 (en) 2000-11-20 2003-07-15 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US6734010B2 (en) * 2001-05-09 2004-05-11 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6541252B1 (en) 2000-05-19 2003-04-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
IL149809A0 (en) * 1999-12-15 2002-11-10 Genentech Inc Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU783689B2 (en) 2000-01-24 2005-11-24 Adnexus Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
US7022479B2 (en) * 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
JP2004500084A (ja) * 2000-01-26 2004-01-08 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトニューレキシン様タンパク質及び該タンパク質をコードするポリヌクレオチド
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
WO2001075178A2 (en) * 2000-04-04 2001-10-11 Enanta Pharmaceuticals, Inc. Methods for identifying peptide aptamers capable of altering a cell phenotype
ES2393535T3 (es) * 2000-04-17 2012-12-26 Dyax Corp. Nuevos métodos para construir bibliotecas de paquetes genéticos que presentan de forma colectiva los miembros de una familia diversa de péptidos, polipéptidos o proteínas
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001079562A1 (en) * 2000-04-18 2001-10-25 Gilead Sciences, Inc. Aptamer based two-site binding assay
US6479262B1 (en) 2000-05-16 2002-11-12 Hercules, Incorporated Solid phase enzymatic assembly of polynucleotides
US6703495B2 (en) * 2000-06-07 2004-03-09 Lexicon Genetics Incorporated Polynucleotides encoding human transporter protein
AU2001266844A1 (en) * 2000-06-09 2001-12-17 Lexicon Genetics Incorporated Novel human seven transmembrane proteins and polynucleotides encoding the same
US6465632B1 (en) * 2000-06-09 2002-10-15 Lexicon Genetics Incorporated Human phosphatases and polynucleotides encoding the same
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6994963B1 (en) 2000-07-10 2006-02-07 Ambion, Inc. Methods for recombinatorial nucleic acid synthesis
WO2002006456A1 (en) * 2000-07-13 2002-01-24 Invitrogen Corporation Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
WO2002008408A2 (en) * 2000-07-21 2002-01-31 Trustees Of Boston University Modular vector systems
US7087415B2 (en) * 2000-07-31 2006-08-08 Athena Biotechnologies, Inc. Methods and compositions for directed gene assembly
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
WO2002011748A1 (en) * 2000-08-07 2002-02-14 Sloan-Kettering Institute For Cancer Research Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
AU2001286792A1 (en) * 2000-08-22 2002-03-04 Lexicon Genetics Incorporated Novel human 7TM proteins and polynucleotides encoding the same
AU2001285326A1 (en) * 2000-08-31 2002-03-13 Lexicon Genetics Incorporated Human kinase proteins and polynucleotides encoding the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU9630501A (en) * 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
AU2002211624A1 (en) * 2000-10-10 2002-04-22 Genencor International, Inc. Information rich libraries
AU2440102A (en) 2000-10-16 2002-04-29 Gilead Sciences Inc Nucleic acid ligands to the prostate specific membrane antigen
EP1624062A3 (en) * 2000-10-27 2006-02-22 Lexicon Genetics Incorporated Human 7tm proteins and polynucleotides encoding them
WO2002046400A2 (en) * 2000-12-08 2002-06-13 The Board Of Trustees Of The University Of Illinois Mutated class ii major histocompatibility proteins
JP2004517622A (ja) 2000-12-11 2004-06-17 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
US6958213B2 (en) 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
WO2002048333A2 (en) * 2000-12-12 2002-06-20 Lexicon Genetics Incorporated Novel human kinases and uses thereof
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
US6852844B1 (en) * 2000-12-20 2005-02-08 Lexicon Genetics Incorporated Human protocadherin proteins and polynucleotides encoding the same
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2002059325A2 (en) * 2000-12-27 2002-08-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
US6849443B2 (en) * 2001-01-23 2005-02-01 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US7582423B2 (en) * 2001-02-02 2009-09-01 Novici Biotech Llc Population of polynucleotide sequence variants
US20040142433A1 (en) * 2001-02-02 2004-07-22 Padgett Hal S. Polynucleotide sequence variants
AU2002314712C1 (en) * 2001-02-02 2008-10-02 Novici Biotech Llc A method of increasing complementarity in a heteroduplex polynucleotide
US7838219B2 (en) * 2001-02-02 2010-11-23 Novici Biotech Llc Method of increasing complementarity in a heteroduplex
US20020127587A1 (en) * 2001-02-13 2002-09-12 Domenica Simms Methods and compositions for isolation of biological macromolecules
CA2439303A1 (en) * 2001-02-22 2002-09-06 Praecis Pharmaceuticals Incorporated Methods for identifying peptides which modulate a biological process
WO2002070655A2 (en) 2001-03-02 2002-09-12 Zymogenetics, Inc. Mouse cytokine receptor
WO2002074978A2 (en) 2001-03-19 2002-09-26 President And Fellows Of Harvard College Nucleic acid shuffling
US7807408B2 (en) * 2001-03-19 2010-10-05 President & Fellows Of Harvard College Directed evolution of proteins
WO2002074932A2 (en) 2001-03-20 2002-09-26 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
WO2002081670A1 (en) * 2001-04-06 2002-10-17 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
CA2443319A1 (en) 2001-04-06 2002-10-17 Lexicon Genetics Incorporated Novel human kinase and polynucleotides encoding the same
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
JP2004528850A (ja) * 2001-05-03 2004-09-24 レンセレアー ポリテクニック インスティテュート 定方向進化の新規方法
US20020193585A1 (en) * 2001-05-25 2002-12-19 Walke D. Wade Novel human transporter proteins and polynucleotides encoding the same
DK1401853T3 (da) * 2001-05-25 2010-11-01 Univ Duke Modulatorer af farmakologiske midler
US6867025B2 (en) 2001-05-29 2005-03-15 Lexicon Genetics Incorporated Human hydroxylases and polynucleotides encoding the same
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20030148380A1 (en) * 2001-06-05 2003-08-07 Belcher Angela M. Molecular recognition of materials
US20050164515A9 (en) * 2001-06-05 2005-07-28 Belcher Angela M. Biological control of nanoparticle nucleation, shape and crystal phase
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
DE10131441A1 (de) * 2001-06-29 2003-01-30 Henkel Kgaa Eine neue Gruppe von alpha-Amylasen sowie ein Verfahren zur Identifizierung und Gewinnung neuer alpha-Amylasen
US20040204669A1 (en) * 2001-07-05 2004-10-14 Hofmann Gunter A. Apparatus for electroporation mediated delivery for drugs and genes
WO2003004604A2 (en) * 2001-07-06 2003-01-16 Genentech, Inc. Phage displayed pdz domain ligands
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
DE10138753B4 (de) * 2001-08-07 2017-07-20 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit Hybrid-Alpha-Amylasen
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
PT1438400E (pt) 2001-10-01 2009-09-10 Dyax Corp Vectores de apresentação eucarióticos de cadeias múltiplas e suas utilizações
US20030073104A1 (en) * 2001-10-02 2003-04-17 Belcher Angela M. Nanoscaling ordering of hybrid materials using genetically engineered mesoscale virus
EP1840211A1 (en) 2001-10-31 2007-10-03 Danisco A/S Pyranosone dehydratase from phanerochaete chrysosporium
JP2007528691A (ja) 2001-11-14 2007-10-18 セントカー・インコーポレーテツド 抗ｉｌ−６抗体、組成物、方法および使用
ES2327398T3 (es) * 2001-11-20 2009-10-29 Duke University Biomateriales interfaciales.
WO2003050914A1 (en) * 2001-12-05 2003-06-19 E-Tenna Corporation Capacitively-loaded bent-wire monopole on an artificial magnetic conductor
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
US20030157534A1 (en) * 2001-12-26 2003-08-21 Manuel Engelhorn DNA immunization with libraries of minigenes encoding degenerate variants of major histocompatability class l restricted epitopes
WO2003057160A2 (en) 2002-01-02 2003-07-17 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030224392A1 (en) * 2002-01-28 2003-12-04 Manuel Engelhorn Method for identification of mutant antigens with enhanced immunogenicity
US7078211B2 (en) * 2002-02-01 2006-07-18 Large Scale Biology Corporation Nucleic acid molecules encoding endonucleases and methods of use thereof
US20030157495A1 (en) * 2002-02-01 2003-08-21 Padgett Hal S. Nucleic acid molecules encoding CEL I endonuclease and methods of use thereof
JP2005517456A (ja) 2002-02-15 2005-06-16 ソマロジック・インコーポレーテッド 核酸リガンドによる標的結合を検出する方法および試薬
US20040025194A1 (en) * 2002-02-22 2004-02-05 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
AU2003217716A1 (en) * 2002-02-25 2003-09-09 Cabot Corporation Custom ligand design for biomolecular filtration and purification for bioseperation
US20030224404A1 (en) * 2002-02-25 2003-12-04 Manuel Vega High throughput directed evolution of nucleic acids by rational mutagenesis
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
JP2005536190A (ja) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
PT1497418E (pt) 2002-04-19 2013-01-25 Dsm Ip Assets Bv Fosfolípases, ácidos nucleicos que as codificam e métodos para as preparar e utilizar
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
DK1504098T4 (da) 2002-05-17 2011-05-23 Alligator Bioscience Ab Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion
CA2488441C (en) * 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
CA2489595C (en) * 2002-06-14 2013-05-28 Simon E. Hufton Recombination of nucleic acid library members
CA2487809A1 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
CA2492463A1 (en) * 2002-07-25 2004-02-05 Archemix Corporation Regulated aptamer therapeutics
EP2275536A1 (en) 2002-08-06 2011-01-19 Verdia, Inc. AP1 amine oxidase variants
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
JP3447009B1 (ja) * 2002-10-29 2003-09-16 實 平垣 構築物用構成体およびその製造方法
CA2504633A1 (en) * 2002-11-21 2004-06-10 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
EP1570085A4 (en) * 2002-12-03 2007-07-25 Archemix Corp PROCESS FOR IN VITRO SELECTION OF 2'-SUBSTITUTED NUCLEIC ACIDS
WO2004058818A2 (en) * 2002-12-26 2004-07-15 Applied Research Systems Ars Holding N.V. Spliced variants of lgr6
US20050079574A1 (en) * 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2194133B1 (en) 2003-03-06 2015-12-02 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
WO2005032496A2 (en) 2003-03-07 2005-04-14 Diversa Corporation Hydrolases, nucleic acids encoding them and mehods for making and using them
US7592434B2 (en) 2003-04-04 2009-09-22 Verenium Corporation Pectate lyases, nucleic encoding them and methods for making and using them
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
US7964714B2 (en) * 2003-05-12 2011-06-21 Potomac Pharmaceuticals Inc. Gene expression suppression agents
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
JP2007529993A (ja) 2003-07-02 2007-11-01 シンジェンタ パーティシペーションズ アーゲー グルカナーゼ、それらをコードする核酸並びにそれらを製造及び使用する方法
CA2530284A1 (en) 2003-07-08 2005-02-03 Genentech, Inc. Il-17 a/f heterologous polypeptides and therapeutic uses thereof
US20050054847A1 (en) * 2003-08-01 2005-03-10 Invitrogen Corporation Compositions and methods for preparing short RNA molecules and other nucleic acids
KR20060069825A (ko) * 2003-08-01 2006-06-22 제넨테크, 인크. 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
JP2007528723A (ja) * 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
JP2005065575A (ja) * 2003-08-22 2005-03-17 Japan Science & Technology Agency フレームシャッフリングによるタンパク質分子多様性集団の作製
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
NZ547558A (en) 2003-11-17 2009-06-26 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1701672A4 (en) * 2003-12-19 2011-04-27 Osteotech Inc TISSUE-BASED MESH FOR BONE REGENERATION
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
PT3385384T (pt) 2004-02-12 2020-06-30 Archemix Llc Terapêuticas com aptâmeros úteis no tratamento de desordens relacionadas com o complemento
US20070066550A1 (en) * 2004-03-05 2007-03-22 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US7569223B2 (en) * 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7785903B2 (en) * 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
DK1745062T3 (da) 2004-04-22 2014-08-11 Regado Biosciences Inc Forbedrede modulatorer af koagulationsfaktorer
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
WO2005106012A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005118647A2 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for c-terminal and bi-terminal display of a heterologous protein
ES2540728T3 (es) 2004-06-16 2015-07-13 Dsm Ip Assets B.V. Método para la decoloración enzimática de feofitina
WO2006029258A2 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101227A (ko) 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
GB0422052D0 (en) 2004-10-04 2004-11-03 Dansico As Enzymes
GB0423139D0 (en) * 2004-10-18 2004-11-17 Danisco Enzymes
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
CA2594356C (en) 2005-01-05 2018-07-17 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1856156A2 (en) 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
WO2006098998A2 (en) 2005-03-10 2006-09-21 Genentech, Inc. Methods and compositions for modulating vascular integrity
BRPI0609140A2 (pt) 2005-03-15 2010-02-17 Verenium Corp celulases, ácidos nucléicos que codificam eles e métodos para a produção e uso deles
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
CN103146708A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
DK2452694T3 (en) 2005-06-30 2019-03-04 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and applications
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20130108481A (ko) 2005-08-19 2013-10-02 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
ES2357626T3 (es) 2005-08-24 2011-04-28 The Rockefeller University Lisinas mutantes de ply-gbs.
WO2007035527A2 (en) 2005-09-15 2007-03-29 Duke University Non-fouling polymeric surface modification and signal amplification method for biomolecular detection
CN101277974A (zh) * 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
ES2527661T3 (es) 2005-11-30 2015-01-28 Abbvie Inc. Método de exploración, proceso para purificar oligómeros Abeta no difundibles, anticuerpos selectivos contra dichos oligómeros Abeta no difundibles y un proceso para fabricar dichos anticuerpos
US20070237764A1 (en) * 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
WO2007092313A2 (en) * 2006-02-03 2007-08-16 Indiana University Research And Technology Corporation Construction of open reading frame libraries and protein structures
CN103602692A (zh) 2006-02-10 2014-02-26 维莱尼姆公司 纤维素分解酶、其编码核酸及制备和使用它们的方法
US8043839B2 (en) 2006-02-14 2011-10-25 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
ES2416104T3 (es) 2006-03-07 2013-07-30 Cargill, Incorporated Aldolasas, ácidos nucleicos que las codifican y métodos para producir y usar las mismas
WO2007103989A2 (en) 2006-03-07 2007-09-13 Verenium Corporation Aldolases, nucleic acids encoding them and methods for making and using them
SI2596807T1 (sl) * 2006-03-08 2016-03-31 Archemix Llc Komplement vezavni aptameri in sredstva proti C5, uporabni pri zdravljenju očesnih motenj
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
AT503902B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CA2658654A1 (en) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
CA3020590A1 (en) 2006-08-04 2009-02-12 Bp Corporation North America Inc. Glucanases, nucleic acids encoding them and methods for making and using them
EP2520935A3 (en) 2006-08-09 2013-02-13 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2008127271A2 (en) 2006-09-08 2008-10-23 Abbott Laboratories Interleukin -13 binding proteins
WO2008032833A1 (en) 2006-09-14 2008-03-20 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
MX2009003034A (es) 2006-09-21 2009-11-18 Verenium Corp Fosfolipasas, acidos nucleicos que las codifican, y metodos de hacerlas y usarlas.
MY184850A (en) 2006-09-21 2021-04-27 Basf Enzymes Llc Phytases, nucleic acids encoding them and method for making and using them
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HUE033455T2 (en) 2006-12-21 2017-12-28 Basf Enzymes Llc Amylases and glucoamylases, nucleic acids encoding them, and methods for their preparation and use
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
WO2008088861A2 (en) * 2007-01-18 2008-07-24 University Of Southern California Gene polymorphisms predictive for dual tki therapy
CA2674721C (en) 2007-01-30 2018-04-03 Verenium Corporation Enzymes for the treatment of lignocellulosics, nucleic acids encoding them and methods for making and using them
US8143046B2 (en) 2007-02-07 2012-03-27 Danisco Us Inc., Genencor Division Variant Buttiauxella sp. phytases having altered properties
JP5675109B2 (ja) * 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
EP2140021B1 (en) 2007-02-22 2012-01-11 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2124952A2 (en) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
ES2975748T3 (es) 2007-06-26 2024-07-12 F Star Therapeutics Ltd Presentación de agentes de unión
MX375114B (es) 2007-07-17 2025-03-06 Somalogic Operating Co Inc Método para generar aptámeros con constantes de disociación mejoradas.
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) * 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2008304192B9 (en) 2007-09-28 2024-02-01 Alexion Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
CN110577945A (zh) 2007-10-03 2019-12-17 维莱尼姆公司 木聚糖酶、编码它们的核酸以及其制备和应用方法
US8957031B2 (en) * 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
WO2009055656A2 (en) 2007-10-26 2009-04-30 Centocor, Inc. Vectors, host cells, and methods of production and uses
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2242843B1 (en) * 2007-12-31 2015-05-27 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
DK2238261T3 (da) 2008-01-03 2014-02-10 Verenium Corp Isomeraser, nukleinsyrer der koder for dem og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0822218A2 (pt) 2008-01-03 2015-06-23 Verenium Corp Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las.
US7682809B2 (en) 2008-01-11 2010-03-23 Agilent Technologies, Inc. Direct ATP release sequencing
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
US9388510B2 (en) 2008-04-24 2016-07-12 Dyax Corp. Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2279248B1 (en) 2008-04-30 2015-04-01 DuPont Nutrition Biosciences ApS Proteins
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US8323651B2 (en) 2008-05-09 2012-12-04 Abbott Laboratories Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
TW201008580A (en) 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
MX2010013236A (es) 2008-06-03 2011-02-24 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CA2728308A1 (en) 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
EP2319869B1 (en) 2008-06-20 2016-08-17 National University Corporation Okayama University ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
KR20110031369A (ko) * 2008-07-08 2011-03-25 아보트 러보러터리즈 프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
EP2810654A1 (en) 2008-07-08 2014-12-10 AbbVie Inc. Prostaglandin E2 binding proteins and uses thereof
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US20100166789A1 (en) * 2008-07-25 2010-07-01 The Regents Of The University Of Colorado Proteins for use in diagnosing and treating infection and disease
US9182406B2 (en) * 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
EP2326668B1 (en) 2008-08-14 2018-01-17 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/il-23 antibodies
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
AU2009307249B2 (en) 2008-10-20 2012-11-01 Gwangju Institute Of Science And Technology Bipodal peptide binder
EP2373692A4 (en) * 2008-12-04 2013-11-20 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
WO2010087972A2 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
PE20121094A1 (es) * 2009-03-05 2012-09-13 Abbvie Inc Proteinas de union a il-17
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
GB0908770D0 (en) 2009-04-24 2009-07-01 Danisco Method
EP2432797B1 (en) 2009-05-21 2016-10-05 BASF Enzymes LLC Phytases, nucleic acids encoding them and methods for making and using them
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN105131112A (zh) 2009-08-29 2015-12-09 Abbvie公司 治疗用dll4结合蛋白
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
JP2013504602A (ja) * 2009-09-14 2013-02-07 ダイアックス コーポレーション 新しく設計したｈｃｃｄｒ３を含む遺伝子パッケージライブラリー
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
EP2510001B1 (en) * 2009-12-08 2015-12-02 AbbVie Deutschland GmbH & Co KG Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
MY160556A (en) 2010-02-18 2017-03-15 Genentech Inc Neuregulin antagonists and use thereof in treating cancer
PH12012501680A1 (en) 2010-02-23 2012-11-05 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
KR20240052894A (ko) 2010-02-24 2024-04-23 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
BR112012021941A2 (pt) 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
WO2011109642A1 (en) 2010-03-03 2011-09-09 Somalogic, Inc. Aptamers to 4-1bb and their use in treating diseases and disorders
RS56904B1 (sr) 2010-03-30 2018-05-31 Janssen Biotech Inc Humanizovna il-25 antitela
AR081452A1 (es) 2010-04-12 2012-09-05 Somalogic Inc APTAMEROS PARA b-NGF Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS MEDIADOS POR b-NGF
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
PT2571532T (pt) 2010-05-14 2017-08-04 Abbvie Inc Proteínas de ligação a il-1
GB201011513D0 (en) 2010-07-08 2010-08-25 Danisco Method
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103282560B (zh) 2010-07-16 2016-08-03 阿迪马布有限责任公司 抗体文库
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP6121903B2 (ja) 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
SG187938A1 (en) 2010-08-26 2013-04-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
CA2811787A1 (en) 2010-10-06 2012-04-19 Bp Corporation North America Inc. Variant cbh i polypeptides
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
SG191312A1 (en) 2010-12-21 2013-07-31 Abbvie Inc Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
EP3153583B1 (en) 2010-12-31 2021-10-20 BioAtla, Inc. Express humanization of antibodies
US9428789B2 (en) 2011-03-21 2016-08-30 Biodesy, Inc. Classification of kinase inhibitors using nonlinear optical techniques
MX370442B (es) 2011-04-21 2019-12-13 Univ Rockefeller Proteínas quiméricas de una lisina de bacteriófago de streptococcus para la detección y tratamiento de bacterias gram positivas.
KR20140061403A (ko) 2011-07-13 2014-05-21 애브비 인코포레이티드 항―ｉｌ―１３ 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
KR20140068062A (ko) 2011-09-15 2014-06-05 제넨테크, 인크. 분화의 촉진 방법
DK2764093T3 (en) 2011-10-05 2018-07-30 Univ Rockefeller DIMER BACTERYPHAGE LYSINES
KR20140084164A (ko) 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
US9220775B2 (en) 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
JP6336397B2 (ja) 2011-12-14 2018-06-06 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 鉄関連障害を診断および治療するための組成物および方法
CA2855840C (en) 2011-12-14 2023-08-29 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc Proteínas de unión específicas duales dirigidas contra il-13 y/o il-17
CA2862424A1 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
CN104507967B (zh) 2012-01-20 2018-10-12 建新公司 抗cxcr3抗体
TR201809967T4 (tr) 2012-01-27 2018-08-27 Abbvie Deutschland Nörit dejenerasyonu ile ilişkili hastalıkların tanısı ve tedavisi için bileşim ve yöntem.
WO2013162654A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of proteins
RU2014133069A (ru) 2012-02-11 2016-04-10 Дженентек, Инк. Транслокации r-спондина и способы с их использованием
KR20170036142A (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
RU2014141617A (ru) 2012-03-16 2016-05-10 Дженентек, Инк. Сконструированные конформационно-стабилизированные белки
US9139863B2 (en) 2012-03-16 2015-09-22 Genentech, Inc. Engineered conformationally-stabilized proteins
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013170191A1 (en) 2012-05-11 2013-11-14 Genentech, Inc. Methods of using antagonists of nad biosynthesis from nicotinamide
EP3508497A1 (en) 2012-05-24 2019-07-10 Mountgate Group Limited Compositions and methods related to prevention and treatment of rabies infection
ES2894852T3 (es) 2012-06-06 2022-02-16 Zoetis Services Llc Anticuerpos anti-NGF caninizados y métodos de los mismos
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
RS60217B1 (sr) 2012-08-31 2020-06-30 Immunogen Inc Dijagnostički testovi i kompleti za detekciju folatnog receptora 1
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
BR112015021423A2 (pt) 2013-03-06 2017-07-18 Genentech Inc métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
GB201308828D0 (en) 2013-03-12 2013-07-03 Verenium Corp Phytase
CA2906417C (en) 2013-03-14 2022-06-21 Robert Ziemann Hcv core lipid binding domain monoclonal antibodies
MX2015011606A (es) 2013-03-14 2016-05-17 Genentech Inc Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
EP2968526A4 (en) 2013-03-14 2016-11-09 Abbott Lab HCV ANTIGEN ANTIBODY COMBINATION TEST AND METHOD AND COMPOSITIONS FOR USE THEREOF
CA2906407A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
GB201308843D0 (en) 2013-03-14 2013-07-03 Verenium Corp Phytase formulation
WO2014139130A1 (en) 2013-03-14 2014-09-18 Adagene Inc. An integrated system for library construction, affinity binder screening and expression thereof
CA2901316A1 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Phi-4 polypeptides and methods for their use
US20160143910A1 (en) 2013-03-15 2016-05-26 Constellation Pharmaceuticals, Inc. Methods of treating cancer and preventing cancer drug resistance
CA2904448A1 (en) 2013-03-15 2014-09-18 Tariq Ghayur Dual specific binding proteins directed against il-1.beta. and/or il-17
WO2014151006A2 (en) 2013-03-15 2014-09-25 Genentech, Inc. Biomarkers and methods of treating pd-1 and pd-l1 related conditions
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
CA2919437A1 (en) 2013-07-25 2015-01-29 Basf Enzymes Llc Phytase
CN106232820A (zh) 2013-08-16 2016-12-14 先锋国际良种公司 杀昆虫蛋白及其使用方法
KR102428492B1 (ko) 2013-08-30 2022-08-03 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 항체 및 분석
HK1226081A1 (zh) 2013-09-12 2017-09-22 Halozyme, Inc. 修饰的抗表皮生长因子受体抗体及其使用方法
CA3175967A1 (en) 2013-09-13 2015-03-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
LT3712174T (lt) 2013-12-24 2022-05-25 Janssen Pharmaceutica Nv Anti vista antikūnai ir fragmentai
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
US10480007B2 (en) 2014-02-07 2019-11-19 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants
US10227608B2 (en) 2014-02-07 2019-03-12 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
HRP20201377T1 (hr) 2014-04-08 2021-02-19 Boston Pharmaceuticals Inc. Vezujuće molekule specifične za il-21 i njihova upotreba
MX2016012830A (es) 2014-04-11 2017-01-05 Medimmune Llc Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
BR112016025751A2 (pt) 2014-05-05 2018-01-16 Regeneron Pharma roedor, e, métodos para fabricar um roedor e um camundongo humanizados e para identificar um composto capaz de modular a ativação de complemento
CN106661622B (zh) 2014-05-23 2020-08-21 豪夫迈·罗氏有限公司 Mit生物标志物和使用它们的方法
EP3154589A1 (en) 2014-06-13 2017-04-19 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015196070A1 (en) 2014-06-20 2015-12-23 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
EP3207143B1 (en) 2014-10-16 2023-11-22 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
AU2015334890B2 (en) 2014-10-24 2021-12-23 Dupont Nutrition Biosciences Aps Proline tolerant tripeptidyl peptidases and uses thereof
EP3172329A1 (en) 2014-10-24 2017-05-31 Danisco US Inc. Method for producing alcohol by use of a tripeptidyl peptidase
CA2967118A1 (en) 2014-11-10 2016-05-19 Medimmune Limited Binding molecules specific for cd73 and uses thereof
JP6847037B2 (ja) 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016106286A1 (en) 2014-12-23 2016-06-30 Biodesy, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
AU2016207026B2 (en) 2015-01-15 2021-12-02 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
BR112017019419B1 (pt) 2015-03-11 2022-10-11 E. I. Du Pont De Nemours And Company Construto de dna, método de obtenção de uma planta transgênica e método para controlar uma população de praga de verme da raiz do milho
EP3286227A2 (en) 2015-04-24 2018-02-28 F. Hoffmann-La Roche AG Multispecific antigen-binding proteins
BR112017024948A2 (pt) 2015-05-19 2018-07-31 Pioneer Hi Bred Int proteínas inseticidas e métodos para uso das mesmas
PE20180193A1 (es) 2015-05-29 2018-01-26 Abbvie Inc Anticuerpos anti-cd40 y sus usos
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
DK3313882T3 (da) 2015-06-24 2020-05-11 Janssen Pharmaceutica Nv Anti-VISTA antistoffer og fragmenter
JP2018518976A (ja) 2015-06-26 2018-07-19 デュポン ニュートリション バイオサイエンシス エーピーエス タンパク質加水分解用アミノペプチダーゼ
CN114672490A (zh) 2015-06-29 2022-06-28 伊缪诺金公司 抗cd123抗体以及其缀合物和衍生物
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3943602A1 (en) 2015-08-06 2022-01-26 Pioneer Hi-Bred International, Inc. Plant derived insecticidal proteins and methods for their use
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
RS60389B1 (sr) 2015-11-10 2020-07-31 Medimmune Llc Vezujući molekuli specifični za asct2 i njihove upotrebe
CN108575091A (zh) 2015-12-18 2018-09-25 先锋国际良种公司 杀昆虫蛋白及其使用方法
US10898483B2 (en) 2015-12-23 2021-01-26 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
EP3420097A1 (en) 2016-02-25 2019-01-02 DuPont Nutrition Biosciences ApS Method for producing a protein hydrolysate employing an aspergillus fumigatus tripeptidyl peptidase
HRP20241557T1 (hr) 2016-03-10 2025-05-23 Acceleron Pharma Inc. Proteini koji vezuju receptor aktivina tipa 2 i njihova uporaba
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP7103950B2 (ja) 2016-04-22 2022-07-20 アクセレロン ファーマ インコーポレーテッド Ａｌｋ７結合性タンパク質及びその使用
IL297519B2 (en) 2016-04-27 2024-06-01 Abbvie Inc Methods for treating diseases in which IL-13 activity is harmful using antibodies to IL-13
CA3018384A1 (en) 2016-05-04 2017-11-09 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
DK3464318T3 (da) 2016-06-02 2021-06-28 Abbvie Inc Glucocorticoidreceptoragonist og immunkonjugater deraf
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
TWI762487B (zh) 2016-06-08 2022-05-01 美商艾伯維有限公司 抗-b7-h3抗體及抗體藥物結合物
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
WO2017215790A1 (en) 2016-06-17 2017-12-21 National Hellenic Research Foundation Systems for recombinant protein production
CA3026113A1 (en) 2016-07-01 2018-01-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
JP2019534858A (ja) 2016-09-09 2019-12-05 ジェネンテック， インコーポレイテッド Ｆｒｉｚｚｌｅｄの選択的ペプチド阻害剤
JP2020500152A (ja) 2016-09-30 2020-01-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
EP3519825B1 (en) 2016-10-03 2025-11-19 Abbott Laboratories Improved methods of assessing gfap status in patient samples
EP3535285B1 (en) 2016-11-01 2022-04-06 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
JP7274417B2 (ja) 2016-11-23 2023-05-16 イミュノア・セラピューティクス・インコーポレイテッド ４－１ｂｂ結合タンパク質及びその使用
CN110088123B (zh) 2016-12-14 2023-10-20 先锋国际良种公司 杀昆虫蛋白及其使用方法
US11213028B2 (en) 2016-12-22 2022-01-04 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CA3049105A1 (en) 2017-01-04 2018-07-12 Lauren O. Bakaletz Dnabii vaccines and antibodies with enhanced activity
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7661008B2 (ja) 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
US11390685B2 (en) 2017-01-06 2022-07-19 Biosion, Inc. ErbB2 antibodies and uses therefore
KR20190113858A (ko) 2017-01-30 2019-10-08 얀센 바이오테크 인코포레이티드 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
BR112019016394A2 (pt) 2017-02-08 2020-04-07 Pioneer Hi Bred Int construto de dna, pilha molecular, pilha de melhoramento, planta transgênica ou progênie da mesma, composição e método para controlar uma população de praga de inseto
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
SG10202111663PA (en) 2017-02-27 2021-12-30 Regeneron Pharma Humanized model of kidney and liver disorders
EP3595445B1 (en) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CA3261113A1 (en) 2017-03-23 2025-10-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
BR112019021612A2 (pt) 2017-04-15 2020-05-12 Abbott Laboratories Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
MX2019012419A (es) 2017-04-21 2019-12-05 Genentech Inc Uso de antagonistas de klk5 para el tratamiento de una enfermedad.
WO2018200742A1 (en) 2017-04-25 2018-11-01 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
US10865238B1 (en) 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
WO2018208882A1 (en) 2017-05-11 2018-11-15 Pioneer Hi-Bred International, Inc. Insecticidal proteins and methods for their use
CN110651190A (zh) 2017-05-25 2020-01-03 雅培实验室 用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
CN110720041B (zh) 2017-05-30 2024-04-26 雅培实验室 用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
US11654135B2 (en) 2017-06-22 2023-05-23 Moonshot Pharma Llc Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
CN110945023B (zh) 2017-07-31 2023-08-18 豪夫迈·罗氏有限公司 基于三维结构的人源化方法
AU2018328187A1 (en) 2017-09-05 2020-03-26 Immunogen, Inc. Methods for detection of folate receptor 1 in a patient sample
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
IL273790B2 (en) 2017-10-04 2025-02-01 Opko Pharmaceuticals Llc Products and methods designed for personalized cancer treatment
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
MA50580A (fr) 2017-11-06 2020-09-16 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
US11022617B2 (en) 2017-12-09 2021-06-01 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase L1 (UCH-L1)
EP3721234A1 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
EP3728321A1 (en) 2017-12-22 2020-10-28 F. Hoffmann-La Roche AG Use of pilra binding agents for treatment of a disease
CA3084064A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
CA3091184A1 (en) 2018-02-14 2019-08-22 Viela Bio, Inc. Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
EP3762015B1 (en) 2018-03-05 2025-12-24 Janssen Biotech, Inc. Guselkumab for use in the treatment of crohn's disease with a dosage regimen
CN111819197B (zh) 2018-03-12 2025-03-11 硕腾服务有限责任公司 抗ngf抗体及其方法
CA3093838A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
US11820791B2 (en) 2018-03-14 2023-11-21 Pioneer Hi-Bred International, Inc. Insecticidal proteins from plants and methods for their use
MX2020009435A (es) 2018-03-14 2020-11-11 Pioneer Hi Bred Int Proteinas con actividad insecticida de plantas y metodos para sus usos.
US12235273B2 (en) 2018-05-04 2025-02-25 Abbott Laboratories HBV diagnostic, prognostic, and therapeutic methods and products
US11708571B2 (en) 2018-05-17 2023-07-25 Bp Corporation North America Inc. Production of 2-keto-3-deoxy-d-gluconic acid in filamentous fungi
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
US20210227810A1 (en) 2018-06-13 2021-07-29 Crystal Bioscience Inc. Production of antibodies by modification of an autonomous heavy chain variable domain by gene conversion
EP3813520A4 (en) 2018-06-13 2022-03-23 Crystal Bioscience Inc. TRANSGENIC CHICKEN PRODUCING ANTIBODIES WITH LONG CDR-H3S STABILIZED BY MULTIPLE DISULPHIDE BRIDGES AND DIVERSIFIED BY GENE CONVERSION
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
EP3824295A4 (en) 2018-07-18 2022-04-27 Janssen Biotech, Inc. PREDICTORS WITH DELAYED ACTION AFTER TREATMENT WITH ANTI-IL23 SPECIFIC ANTIBODIES
WO2020041360A1 (en) 2018-08-21 2020-02-27 Quidel Corporation Dbpa antibodies and uses thereof
CA3110656A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
EP3847262A1 (en) 2018-09-07 2021-07-14 Basf Plant Science Company GmbH Improved method for the production of high levels of pufa in plants
AU2019334672A1 (en) 2018-09-07 2021-03-25 Basf Plant Science Company Gmbh Improved method for the production of high levels of PUFA in plants
DE202019006083U1 (de) 2018-09-24 2024-09-09 Janssen Biotech, Inc. Anti-IL-12/IL-23p40-Antikörper zur Verwendung in der Behandlung von Colitis ulcerosa
JP7541513B2 (ja) 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
TW202035445A (zh) 2018-10-10 2020-10-01 美商帝洛斯療法股份有限公司 抗lap抗體變異體及其用途
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
US12467062B2 (en) 2018-12-21 2025-11-11 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
BR112021013903A2 (pt) 2019-01-15 2021-09-21 Janssen Biotech, Inc. Composições e métodos de anticorpos anti-tnf para o tratamento da artrite idiopática juvenil
IL284794B2 (en) 2019-01-23 2025-10-01 Janssen Biotech Inc Anti-TNF antibody preparations for use in methods of treating psoriatic arthritis
US12509515B2 (en) 2019-03-11 2025-12-30 Memorial Sloan Kettering Cancer Center CD22 antibodies and methods of using the same
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
JP7662529B2 (ja) 2019-03-14 2025-04-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｔｎｆ抗体組成物を産生するための方法
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
SG11202110525QA (en) 2019-05-09 2021-10-28 Genentech Inc Methods of making antibodies
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
US20220324959A1 (en) 2019-06-03 2022-10-13 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
AU2020289070A1 (en) 2019-06-03 2022-02-03 Janssen Biotech, Inc. Anti-TNF antibody compositions, and methods for the treatment of Psoriatic Arthritis
BR112021024349A2 (pt) 2019-06-04 2022-03-22 Janssen Biotech Inc Método seguro e eficaz para tratar artrite psoriática com anticorpo específico anti-il23
KR20220032066A (ko) 2019-07-08 2022-03-15 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막을 파괴하기 위한 항체 조성물
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021127547A2 (en) 2019-12-19 2021-06-24 Quidel Corporation Monoclonal antibody fusions
CN115135762A (zh) 2019-12-20 2022-09-30 巴斯夫欧洲公司 降低萜烯的毒性和增加微生物的生产潜力
WO2021159024A1 (en) 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021211331A1 (en) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021224823A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
IL297437A (en) 2020-05-13 2022-12-01 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CN115516102B (zh) 2020-06-04 2025-10-31 艾瑟拜奥尼克斯公司 合成的檀香烯合酶
CA3189402A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
BR112022027035A2 (pt) 2020-07-14 2023-04-11 Pioneer Hi Bred Int Proteínas inseticidas e métodos para uso das mesmas
AU2021315081A1 (en) 2020-07-30 2023-03-30 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-IL12/IL23 antibody
EP4193149A1 (en) 2020-08-04 2023-06-14 Abbott Laboratories Improved methods and kits for detecting sars-cov-2 protein in a sample
EP4193151A1 (en) 2020-08-04 2023-06-14 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
CA3193594A1 (en) 2020-09-11 2022-03-17 Medimmune Limited Therapeutic b7-h4 binding molecules
CN116615455A (zh) 2020-09-12 2023-08-18 免疫医疗有限公司 用于抗b7h4抗体-药物缀合物疗法的评分方法
US20230374591A1 (en) 2020-10-08 2023-11-23 The Trustees Of Dartmouth College Methods and agents for treating, preventing, diagnosing, and evaluating therapy for fibrotic, autoimmune, and inflammatory conditions
WO2023102384A1 (en) 2021-11-30 2023-06-08 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
WO2022119841A1 (en) 2020-12-01 2022-06-09 Abbott Laboratories Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4015626A1 (en) 2020-12-18 2022-06-22 Isobionics B.V. Enzymes and methods for fermentative production of monoterpene esters
WO2022147147A1 (en) 2020-12-30 2022-07-07 Abbott Laboratories Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
IL305836A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A method for treating psoriatic arthritis patients with insufficient response to TNF therapy with a specific anti-IL23 antibody
JP2024511078A (ja) 2021-03-17 2024-03-12 レセプトス エルエルシー 抗ｉｌ－１３抗体を用いてアトピー性皮膚炎を処置する方法
US12049506B2 (en) 2021-03-18 2024-07-30 Medimmune Limited Therapeutic binding molecules
EP4337689A1 (en) 2021-05-12 2024-03-20 Applied Biomedical Science Institute Binding polypeptides against sars cov-2 and uses thereof
JP2024519858A (ja) 2021-05-18 2024-05-21 アボット・ラボラトリーズ 小児対象における脳損傷を査定する方法
US20220372129A1 (en) 2021-05-20 2022-11-24 Janssen Biotech, Inc. Method of Treating Inflammatory Bowel Disease with a Combination Therapy of Antibodies to IL-23 and TNF Alpha
AU2022293389A1 (en) 2021-06-14 2024-01-04 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
EP4367136A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP4367137A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
KR20240034215A (ko) 2021-07-09 2024-03-13 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생산하기 위한 제조 방법
BR112024001952A2 (pt) 2021-08-02 2024-04-30 Basf Se Usos de alfa-ionilidenoetano, de uma alfa-ionilidenoetano sintase e de uma célula hospedeira, métodos para preparar um ou mais compostos aromáticos, para perfumar um produto, conferir e/ou intensificar um odor ou sabor e para produzir alfa-ionona, composto ou composição aromática e/ou composição de fragrância e/ou produto perfumado ou com fragrância, produto perfumado ou com fragrância, e, célula hospedeira para produzir alfa-ionona
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
EP4392783A1 (en) 2021-08-27 2024-07-03 Abbott Laboratories Methods for detecting immunoglobulin g, subclass 4 (igg4) in a biological sample
WO2023034777A1 (en) 2021-08-31 2023-03-09 Abbott Laboratories Methods and systems of diagnosing brain injury
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
EP4409294A1 (en) 2021-09-30 2024-08-07 Abbott Laboratories Methods and systems of diagnosing brain injury
EP4423126A1 (en) 2021-10-29 2024-09-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
KR20240107176A (ko) 2021-11-15 2024-07-08 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
EP4448179A1 (en) 2021-12-17 2024-10-23 Abbott Laboratories Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2023150652A1 (en) 2022-02-04 2023-08-10 Abbott Laboratories Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202348252A (zh) 2022-02-16 2023-12-16 英商梅迪繆思有限公司 用治療性結合分子治療癌症的組合療法
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
AU2023273357A1 (en) 2022-05-18 2025-01-09 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
CA3257731A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories OUTSIDE THE LABORATORY, MAGNETIC SYSTEMS AND ANALYSES FOR DETERMINING GLIOFIBRILLARY ACID PROTEIN IN BIOLOGICAL SAMPLES
CA3265992A1 (en) 2022-09-15 2024-03-21 Abbott Laboratories BIOMARKERS AND METHODS FOR DIFFERENTIATING BETWEEN MILD AND VERY MILD TRAUMATIC BRAIN INJURY
AU2023343487A1 (en) 2022-09-15 2025-03-20 Abbott Laboratories Hbv diagnostic, prognostic, and therapeutic methods and products
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2024169990A1 (zh) 2023-02-13 2024-08-22 浙江大学绍兴研究院 双特异性抗体及其应用
WO2024211475A1 (en) 2023-04-04 2024-10-10 Abbott Laboratories Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226969A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
CN121443312A (zh) 2023-05-03 2026-01-30 詹森生物科技公司 用抗IL-23和TNF α抗体的组合治疗克罗恩氏病的方法
CN121443311A (zh) 2023-05-03 2026-01-30 詹森生物科技公司 用抗IL-23和TNFα抗体的组合治疗溃疡性结肠炎的方法
KR20260011157A (ko) 2023-05-12 2026-01-22 제넨테크, 인크. 항체 점도를 낮추는 방법 및 조성물
US20250051463A1 (en) 2023-07-31 2025-02-13 Astrazeneca Ab Cd123 antibody-drug conjugates and methods of using the same
US20250361320A1 (en) 2024-02-27 2025-11-27 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2026003761A1 (en) 2024-06-27 2026-01-02 Janssen Biotech, Inc. Methods of treating ulcerative colits with anti-il23 specific antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4321365A (en) * 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4293652A (en) * 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4271145A (en) * 1979-10-22 1981-06-02 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4879219A (en) * 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4490358A (en) * 1982-03-01 1984-12-25 President And Fellows Of Harvard College Screening vaccines and immunization process
USRE32833E (en) * 1982-03-01 1989-01-17 President And Fellows Of Harvard College Screening vaccines and immunization process
US4366264A (en) 1982-04-16 1982-12-28 Stanley Wawzonek Use of calcium metasilicate (wollastonite) as a formaldehyde suppressant for urea formaldehyde resins
DE3300632A1 (de) * 1982-12-13 1984-07-12 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
US4634678A (en) * 1982-12-13 1987-01-06 Molecular Genetics Research And Development Limited Partnership Plasmid cloning and expression vectors for use in microorganisms
DE3303173A1 (de) * 1982-12-13 1984-08-02 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
DE3246071A1 (de) * 1982-12-13 1984-06-14 Christian Dipl.-Ing. 8900 Augsburg Strobel Verfahren genetischer analyse und synthese
US4719179A (en) * 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US4959312A (en) * 1985-05-31 1990-09-25 The University Of Tennessee Research Corporation Full spectrum mutagenesis
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genetic Engineering, Vol.1, ed. *
SETLOW, J.K., und HOLLAENDER, A.: Plenum Press, New York und London, 1979, S.15-36 *

Also Published As

Publication number Publication date
US5817483A (en) 1998-10-06
US5976862A (en) 1999-11-02
JPH0856667A (ja) 1996-03-05
US5723323A (en) 1998-03-03
EP1186660A3 (fr) 2002-03-20
US6569641B1 (en) 2003-05-27
CA1341595C (en) 2009-04-28
JP2002325594A (ja) 2002-11-12
FR2579618A1 (fr) 1986-10-03
GB8628313D0 (en) 1986-12-31
DE3590766T (enExample) 1987-04-23
DE3587814T2 (de) 1994-11-10
CA1339937C (en) 1998-06-30
DE3588239T2 (de) 2003-01-02
US5824514A (en) 1998-10-20
IN165561B (enExample) 1989-11-18
DE3546806C2 (enExample) 1991-03-28
EP1186660A2 (fr) 2002-03-13
CH0229046H1 (de) 1998-07-15
EP0229046A1 (fr) 1987-07-22
US20040161816A1 (en) 2004-08-19
JP2004089197A (ja) 2004-03-25
IN169027B (enExample) 1991-08-17
EP0590689B2 (fr) 2006-08-16
JPS62502235A (ja) 1987-09-03
CN86102090A (zh) 1986-11-05
DE3587814D1 (de) 1994-06-09
DE229046T1 (de) 1987-12-17
DE3546807C2 (enExample) 1991-03-28
US5814476A (en) 1998-09-29
FR2579618B1 (fr) 1987-12-24
EP0229046B1 (fr) 1994-05-04
EP0590689B1 (fr) 2002-05-22
GB2183661A (en) 1987-06-10
HK20292A (en) 1992-03-27
EP0590689A2 (fr) 1994-04-06
AU4434585A (en) 1986-10-23
EP0590689A3 (enExample) 1994-04-20
WO1986005803A1 (fr) 1986-10-09
SG7992G (en) 1992-03-20
DE3588239T3 (de) 2007-03-08
DE3588239D1 (de) 2002-06-27
GB2183661B (en) 1989-06-28
JP2584613B2 (ja) 1997-02-26

Similar Documents

Publication Publication Date Title
DE3590766C2 (enExample)
DE19826758C1 (de) Darstellung von linearen kovalent geschlossenen DNA-Molekülen als Expressionskonstrukte
DE69128362T2 (de) Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
DE68929510T2 (de) Nukleotidsequenzen, die für ein Protein mit Ureaseaktivität kodieren
CH684892A5 (de) DNA, welche für ein Polypeptid mit der Aktivität von menschlichem Interferon und beta 2 kodiert und Verfahren zu dessen Herstellung.
DD159782A5 (de) Verfahren zur herstellung eines eine immunologische oder biologische aktivitaet von humanleukozyten-interferon aufweisendes polypeptids
DE60021188T2 (de) Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben
DE69530119T2 (de) Verfahren zur kontrollierten synthese von beliebigen peptidmischungen kodierende polynukleotidmischungen
EP1144634A2 (de) Komplexbildende proteine
DE3641040A1 (de) Flavivirus-antigen und verfahren zu seiner herstellung
EP0316695B1 (de) Rekombinante HIV-2 Polypeptide
DE3622221A1 (de) Verfahren zur gentechnologischen gewinnung von proteinen unter verwendung gramnegativer wirtszellen
DE69318495T2 (de) Verfahren zur Reinigung des Big-Endothelin Proteins
CH640268A5 (en) Process for the preparation of filamentous hybrid phages, novel hybrid phages and their use
EP0440207B1 (de) Expression von HIV1- und 2- Polypeptiden und deren Verwendung
DE68923496T2 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
EP1362125B8 (de) Verfahren zur identifizierung biologisch aktiver strukturen mikrobieller erreger
DE3788592T2 (de) Plasmidvektor zur Expression im Bazillus, dessen Umwendung für die Klonierung des menschlichen Wachstumshormongens und Verfahren zur Produktion des Hormons.
DE3688816T2 (de) Dns-sequenz.
EP2439276A1 (de) Verfahren zur semi-synthetischen Herstellung hochreiner "MiniCircle" DNA-Vektoren aus Plasmiden
DE69434072T2 (de) Regulierende nukleinsaeuresequenzen und verwendungen
DE3689993T2 (de) Vektor für Expression und Sekretion von Produkten von heterologen Genen in Bacillus Subtilis.
DE102004010928B4 (de) Protein zur Bindung prokaryonter DNA sowie Verfahren zur Trennung und Anreicherung prokaryonter DNA
EP0603672A2 (de) Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
WO2006133758A2 (de) Vorrichtung zur anreicherung/abtrennung von nicht-methylierte cpg-motive enthaltender dna

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
Q172 Divided out of (supplement):

Ref country code: DE

Ref document number: 3546807

Q172 Divided out of (supplement):

Ref country code: DE

Ref document number: 3546806

AC Divided out of

Ref country code: DE

Ref document number: 3546807

Format of ref document f/p: P

Ref country code: DE

Ref document number: 3546806

Format of ref document f/p: P

D2 Grant after examination
AC Divided out of

Ref country code: DE

Ref document number: 3546807

Format of ref document f/p: P

Ref country code: DE

Ref document number: 3546806

Format of ref document f/p: P

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: KAUFFMANN, STUART ALAN, SANTA FE, N.MEX., US

8381 Inventor (new situation)

Free format text: BALLIVET, MARC, GENF/GENEVE, CH KAUFFMAN, STUART ALAN, BRYN MAWR, PA., US